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Abstract
Tumor development and tumor progression is not only determined by the corresponding tumor cells but also by
the tumor microenvironment. This includes an orchestrated network of interacting cell types (e.g. immune cells,
endothelial cells, fibroblasts, and mesenchymal stroma/stem cells (MSC)) via the extracellular matrix and soluble
factors such as cytokines, chemokines, growth factors and various metabolites. Cell populations of the tumor
microenvironment can interact directly and indirectly with cancer cells by mutually altering properties and
functions of the involved partners. Particularly, mesenchymal stroma/stem cells (MSC) play an important role during
carcinogenesis exhibiting different types of intercellular communication. Accordingly, this work focusses on diverse
mechanisms of interaction between MSC and cancer cells. Moreover, some functional changes and consequences
for both cell types are summarized which can eventually result in the establishment of a carcinoma stem cell niche
(CSCN) or the generation of new tumor cell populations by MSC-tumor cell fusion.
Keywords: MSC, Mesenchymal stroma/stem cells, Tumor cell signaling, Tumor microenvironment, Cellular
interaction, Cell fusion
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Background
Tumor microenvironment and associated cell populations
Solid tumors can be regarded as a complex organ with
tumor cells and a variety of differentially organized cell
types, establishing a certain immune status, contributing
to blood vessel formation and neovascularization, and
building an extracellular matrix which enables the asso-
ciated cell populations to communicate within this
tumor microenvironment (TME) [1, 2]. For further in-
sights in tumor development and chemotherapeutic ap-
proaches, it is indispensable to understand the interplay
of specific components of the TME, the occurring cellu-
lar communication processes and the resulting functions
of this network between cancer cells and the various
tumor-associated cell populations.
Predominant cell types within the TME are repre-
sented by immune cells, fibroblasts, pericytes, endothe-
lial cells, mesenchymal stroma/stem cells and sometimes
adipocytes [3]. Immune cells present in the TME involve
cells from both, the innate and adaptive immune system
whereby lymphocytes represent the majority of tumor-
infiltrating immune cells [4]. It is not surprising that im-
mune responses inhibit tumor development but recent
studies have also proposed that immune cells can pro-
mote cancer growth. CD8+ T cells and CD4 TH1 T cells
mainly exhibit anti-cancer effects since strong infiltra-
tion of tumor tissue by these cell types is associated with
favorable prognosis in many solid tumors including
breast, ovarian, cervical, lung and colorectal cancer [5].
In contrast, other T lymphocyte populations such as
TH2 and Treg cells have been correlated with poor
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clinical outcome in several cancer types [5]. Likewise, B
lymphocytes are attributed a dual role in tumorigenesis.
Whereas high numbers of B cells in the tumor stroma
are linked to favorable prognosis in breast cancer, mouse
models revealed opposite results assigning a tumor pro-
moting role for B lymphocytes [6, 7]. Moreover, natural
killer and natural killer T cells also found in the TME are
proposed to support favorable clinical outcome [3, 8].
Tumor-associated macrophages and myeloid suppressive
cells represent tumor-promoting immune cells together
with their derived cytokines IL-6, IL1β, IL23 and TNFα
[9]. For instance, tumor-associated macrophages can
interact with metastasizing breast cancer cells in the lung
via VCAM-1 and promote tumor cell survival. Further-
more, released pro-inflammatory cytokines such as TNFα
contribute to increased migration and invasiveness of
breast and ovarian cancer cells [10].
In perivascular niches of tumor blood vessels peri-
cytes are predominantly present and can associate with
vascular endothelial cells by contributing to the forma-
tion of blood capillaries [11]. In contrast to normal
healthy vasculature, tumor vessels display an abnormal
physiology due to aberrant pericyte coverage and leaky
endothelial layers upon increasing hypoxia [11]. Thus,
normalization of tumor vasculature to enhance drug
delivery and to reduce hypoxia in the tumor stroma
might be a promising therapeutic approach since low
pericyte coverage is associated with poor prognosis and
pericyte depletion has been correlated with enhanced
hypoxia and metastasis [12].
Further cell populations are represented by stromal
cells or fibroblasts within the TME. The so-called can-
cer- or carcinoma-associated fibroblasts (CAFs) which
are derived from various precursors like aberrant mesen-
chymal stroma/stem cells (MSC) or endothelial cells se-
crete a plethora of growth factors, cytokines, chemokines,
structural protein components, and metabolites that com-
municate with tumor cells and promote oncogenesis by
activating cell proliferation, tumor angiogenesis and inva-
sive properties [3]. Thus, aberrant tumor-associated MSC
can acquire different functions following interaction with
tumor cells including enhanced secretion of TGF-β to
contribute to epithelial-to-mesenchymal transition (EMT)
and immune-suppressive activities. Moreover, these ab-
errant MSC release VEGF for neo-vascularization
within the TME and they produce CXCL12 (=SDF1
(stromal cell-derived factor 1)) to support tumor cell
growth and survival [3].
Likewise, MSC are one of the key players within the
TME and can either inhibit or promote tumor cell growth
by distinct types of cellular interaction [13]. Reduction of
tumor growth by MSC can be mediated via inhibited
angiogenesis, suppressed Wnt and AKT signaling, or in-
duction of cell cycle arrest and apoptosis [14, 15].
MSC are recruited to tumor sites and can be activated
by certain stimuli such as TGF-β1 to develop a CAF-like
phenotype [16].
In addition to a variety of different cell populations in
the tumor microenvironment, the extracellular matrix
(ECM) also plays an important role in the regulation of
tumor development und progression. The ECM does
not only provide a structural scaffold for the tumor
stroma with fibrous proteins such as elastin, collagen
and fibronectin, and proteoglycans like chondroitin
sulfate and hyaluronic acid, but in addition, ECM is
abundant source of soluble factors including growth fac-
tors, angiogenic factors, cytokines and chemokines. This
dynamic and complex network contributes to the inter-
cellular cross-talk with cancer cells. During tumor devel-
opment the ECM is usually dysregulated, remodeled and
appears disorganized [17, 18]. Collagens are the most
abundant fibrous proteins in the extracellular matrix.
Nevertheless, collagen deposition and cross-linking or
tight association with other structural matrix proteins
such as elastins, laminins or fibronectin has been associ-
ated with cancer invasion and metastasis [19]. Cross-
linking of collagen by modifying enzymes such as lysyl
oxidases leads to a more rigid phenotype of the whole
tumor [20]. Stiffness of the tumor stroma causes intra-
cellular contraction and a more rigid cytoskeleton which
in turn leads to a higher migratory capacity [17].
Taken together, the tumor microenvironment contains
a variety of initially non-malignant cell types (immune
cells, endothelial cells, fibroblasts, MSC) which develop
tumor-associated functionalities together with soluble
factors and ECM components that all communicate with
cancer cells thereby inhibiting and promoting tumori-
genesis. Nonetheless, it is important to strengthen that
the TME is a dynamic and heterogeneous environment
whose total composition varies between tumors and pa-
tients. However, the tumor stroma exhibits common fea-
tures of these distinct cell types which may serve as
interesting therapeutic targets [18].
Role of mesenchymal stroma/stem cells and possible
interactions
MSC are multipotent cells that preferentially reside in
perivascular niches of nearly all human tissues and or-
gans like bone marrow, adipose tissue, heart or lung and
neonatal tissues including placenta, amniotic membranes
or umbilical cord [21–24].
Apart from various sources and heterogeneous popula-
tions, MSC exhibit certain common properties ranging
from the expression of surface markers (CD73, CD90,
CD105) to the differentiation along the adipogenic,
chondrogenic and osteogenic lineage [25]. Their func-
tions are extremely diverse and depend on the tissue-
specific origins and the special microenvironment in
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which MSC are embedded. Accordingly, in vitro cultured
MSC can develop different morphologies and properties
whereby long-term stemness can be maintained which in-
cludes MSC cultures for up to 10 passages without loss of
proliferative capacity, telomerase activity or differentiation
capacity [26–28].
In addition to the MSC heterogeneity, subpopulations are
characterized with altered proliferative capacity and aging
properties [29] which may also include epigenetic changes.
Selective MSC subtypes carry additional surface markers
such as Stro-1 [30], CD146 [31], the chemokine receptors
VCAM-1 (CD106) and ICAM-1 (CD54) [32] predomin-
antly found in bone marrow-derived MSC, CD271 [33], or
the more embryonic like stem cell markers Oct-4 and Sox2
[34], which accompany the multi-facetted MSC functional-
ities and affect interactions with other cell types.
MSC are recruited to sites of injury to support tissue
repair, stem cell homeostasis and immunomodulation.
Similar functions are displayed by MSC during tumor
development, whereby permanently proliferating and in-
vasively growing tumor cells create an inflammatory
microenvironment displaying a certain kind of “wound
that never heals” [35]. Thereby, MSC exhibit tissue
repair functions and support angiogenesis which simul-
taneously contributes to promote the growth of cancer
cells [35, 36]. Migration of MSC towards the inflamma-
tion site leads to cellular interactions that occur both
directly via gap junctions, membrane receptors and
nanotubes and indirectly via soluble structures and
factors. Through releasing of different endocrine and
paracrine signals, MSC stimulate neighbored cells with
pro- and/or anti-tumorigenic activities. In turn, MSC
can be stimulated by tumor cells to develop an aberrant
tumor-associated phenotype [14].
Direct and indirect interaction of MSC with tumor cells
Different types of cross-talk between MSC and cancer
cells both directly and indirectly are illustrated in Figs. 1
and 2, respectively. Several direct and/or indirect mecha-
nisms of interaction contribute to MSC-mediated stimu-
lation of cancer cell growth including Notch signaling,
nanotube formation, gap junctional intercellular communi-
cation, and/or the exchange of cytokines/chemokines,
extracellular vesicles and exosomes [36–38]. It is thus
important to emphasize that these different types of indir-
ect and direct interactions are always multidirectional,
therefore affecting and altering both, the tumor cells as
well as the MSC or other cellular partners.
Indirect interaction of MSC with tumor cells
Cytokines, chemokines and growth factors
Indirect communication proceeds via secretion of sol-
uble molecules (e.g. growth factors, cytokines, and che-
mokines) that might function as substrates for specific
receptors of neighboring cells to activate intracellular
signaling pathways. Activated MSC produce and se-
crete a large variety of bioactive molecules suggesting
MSC as Medicinal Signaling Cells [39]. MSC-mediated
release of these biological compounds can affect adja-
cent populations like tumor cells as cellular modula-
tors. For instance, previous studies revealed that
secretion of the CC-chemokine ligand 5 (CCL5) by
MSC also known as RANTES (regulated on activation,
normal T cell expressed and secreted) can interact
with appropriate chemotactic cytokine receptors such
as CCR1, CCR3 or CCR5 [35]. Moreover, CCL5 can
activate the G-protein coupled receptor GPR75 in
breast cancer cells in a paracrine manner. Such CCL5
signaling among further stimuli resulted in acceler-
ation of migratory, invasive and metastatic capacity of
the breast cancer cells [35] (Fig. 1).
Metabolites
Various metabolites within the TME released and
exchanged by the different interacting cell populations
strongly affect the progress of malignancy and contrib-
ute to alter tumor cell properties such as motility, sur-
vival and self-renewal. These effects are relayed in part
by altered energy turnover and consumption whereby
lactate, glutamine and keton bodies contribute to a func-
tional change of cancer cells toward an OXPHOS addicted
phenotype [40].
Besides the secretion of cytokines and chemokines into
the tumor stroma, several metabolites such as prosta-
glandins or indoleamine 2,3-dioxygenase (IDO) repre-
sent further released soluble factors stimulating cells in a
paracrine manner and contributing to the interaction
network of the TME [41, 42].
Previous studies observed that cyclic adenosine mono-
phosphate (cAMP) can inhibit DNA damage-induced
p53 accumulation via activation of protein kinase A
(PKA) resulting in increased survival of lymphoblastic
leukemia cells [43, 44]. In this context, MSC-derived
prostaglandin E2 contributed to protect lymphoblastic
leukemia cells from DNA-damage induced p53 accumu-
lation and cell death via PKA supporting a tumor pro-
moting role of MSC in the TME [45, 46].
A close metabolic coupling of MSC was demonstrated
with osteosarcoma cells whereby tumor cell-induced oxi-
dative stress in MSC was associated with higher levels of
lactate and lactate efflux receptors. Consequently, osteo-
sarcoma cells increased expression of lactate influx recep-
tors whereby lactate secreted by MSC and incorporated
by osteosarcoma cells elevated ATP production and in-
creased migratory capacity of the cancer cells [47]. In
general, metabolic modifications within the TME includ-
ing osmolarity, hypoxia or acidification influence tumor
cell growth and appropriate malignancy [48].
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Microparticles
Another indirect interplay between MSC and cancer
cells is represented by the exchange of microparticles
including exosomes and microvesicles. Whereas exo-
somes are defined as small homogeneous membrane
particles of endocytic origin ranging in size from 40 to
100 nm, microvesicles are directly shed from the plasma
membrane into the extracellular environment represent-
ing a larger and heterogeneous population with 50 to
1000 nm in diameter [49]. Although both types of
microparticles differ in size, origin and releasing mech-
anism, exosomes and microvesicles contain a large panel
of proteins, functional mRNAs and regulatory micro-
RNAs (miRs) which contribute to the cellular interplay
between MSC and cancer cells within the tumor micro-
environment and thereby altering the functionality of
recipient cells [37].
Previous results demonstrated that MSC-derived
exosomes can modulate the function of tumor cells by
induction of MMP-2 and ecto-5’-nucleotidase activity
resulting in a more complex tumor microenvironment
with higher tumor heterogeneity [37, 50]. Alternatively,
MSC-derived exosomes also contain tumor supportive
miRs which enhance tumor growth in vivo [51]. Vice
versa, cancer cells secrete exosomes as well and recent
work demonstrated that prostate cancer cell-derived
exosomes stimulate the differentiation of bone marrow-
derived MSC into pro-angiogenic myofibroblasts with
tumor growth promoting functions [52].
Anti-tumor effects have been also observed with micro-
vesicles derived from human umbilical cord Wharton’s
jelly MSC which inhibit bladder tumor cell growth via cell
cycle arrest and induction of apoptosis, both in vitro and
in vivo [53].
Although functional mechanisms for these controver-
sial observations of tumor promoting versus tumor inhi-
biting roles of MSC-derived microvesicles and exosomes
remain to be elucidated, it appears conceivable that the
cargo of these microparticles which depends on the acti-
vation status and state of development of the originating
MSC is primarily responsible for the type of action on
tumor cells.
Direct interaction of MSC with tumor cells
Notch signaling
Notch signaling plays an important role in fundamen-
tal processes such as support of tissue repair or
regulation of various immune cell functions [54].
a c
b d
Fig. 1 Indirect interactions between mesenchymal stroma/stem cells and cancer cells. a Cytokines, chemokines, growth factors: MSC secrete a
plethora of soluble factors that can bind as substrates to appropriate receptors on the cell surface of cancer cells and vice versa for mutual
activation of signaling pathways. b Metabolites: Likewise, MSC-released metabolites such as prostaglandin E2, kynurenine or galectin-1 can act in
a paracrine manner on cancer cells altering their properties and functions [14]. c Exosomes: Both, MSC and cancer cells, secrete exosomes for the
exchange of small molecules including protein, mRNAs and microRNAs. d Microvesicles: Besides exosomes, microvesicles represent a different
type of microparticles for the exchange of small molecules such as mRNAs or microRNAs affecting tumor cells and MSC in mutual ways
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Activation of notch signaling involves ligand binding
to the notch receptor, cleavage of the intracellular do-
main of the notch receptor by a presenilin-γ-secretase
and translocation of this cleavage domain into the nu-
cleus thereby resulting in trans-activation of down-
stream target genes [55] (Fig. 2).
Previous experiments indicated a functional involve-
ment of the notch pathway during the interaction be-
tween MSC and breast cancer cells [36]. Inhibition of
notch signaling via N-[N-(3,5-difluorophenacetyl-lala-
nyl)]-S-phenylglycine t-butyl ester (DAPT), a γ-secretase
inhibitor, reduces MSC-mediated CD90 expression and
Fig. 2 Direct interactions between mesenchymal stroma/stem cells and cancer cells. a Notch signaling: A prominent example for direct cell-to-
cell interaction is represented by Notch signaling. DAPT, a Notch signaling inhibitor, was shown to decrease functional alterations of breast cancer
cells after co-culture with MSC underlining the involvement of Notch signaling in MSC-cancer cell interactions. b GJIC: Both MSC and cancer cells
build gap junctions for intercellular communication. Gap junctional intercellular communication (GJIC) can be inhibited by gap junction inhibitor
carbenoxolone (CBX) resulting in lesser interactions and functional alterations of cancer cells and MSC. c Nanotube formation: Long and thin
plasma membrane structures formed between MSC and cancer cells allow the transport of small molecules and organelles for cellular cross-talk
leading to altered functions and phenotype. d Trogocytosis: An exchange of whole plasma membrane fragments via an active transfer outlines a
further possible interaction type between MSC and cancer cells resulting in structural and functional alterations of the recipient cell. e Cell fusion:
In rare cases, mesenchymal stem cells have the capacity to fuse with various cancer cell types such as breast, ovarian, lung and gastric cancer
cells. The molecular mechanism about the formation of such cancer hybrid cells is still unknown
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growth of breast cancer cells in co-culture experiments
[36, 56]. Moreover, DAPT could partially reduce MSC-
induced EMT in pancreatic cancer cells emphasizing the
involvement of notch signaling during MSC-cancer cell
interactions [57].
Gap junctional intercellular communication (GIJC)
Gap junctions connect adjacent cells for intercellular,
direct communication called gap junctional intercellu-
lar communication (GJIC) which can regulate cell
growth and differentiation or maintain tissue homeo-
stasis. One gap junction channel is composed of two
hemi-channels from each interacting cell. One hemi-
channel is formed by 6 connexin protein subunits and
each connexin in turn features four transmembrane do-
mains. Typically small molecules and second messenger
such as cAMP and Ca2+-ions are transported through
gap junctions [58].
Acquisition of CD90 by breast cancer cells after co-
culture with MSC is associated with GJIC signaling since
carbenoxolone, a gap junction inhibitor, reduces MSC-
mediated CD90 expression of breast cancer cells [36].
Nanotubes
Nanotubes represent thin, dynamic cytoplasmic protru-
sions which connect two cells enabling the exchange of
a variety of biological cargo ranging from organelles
such as mitochondria to small molecules including cal-
cium ions and glycoproteins over longer distances [59].
Besides exchange of cargo between tumor cells them-
selves [60], cancer cells have been reported to form
nanotubes with MSC as well [61]. In particular, breast
cancer cells MDA-MB-231 acquire mitochondria from
bone-marrow derived MSC via nanotubes resulting in al-
tered metabolic activity and increased proliferative and
invasive capacity [61].
Trogocytosis
A further mechanism for direct cross-talk between MSC
and cancer cells is displayed by trogocytosis. This type of
direct cellular interaction was firstly described between
immune cells for the transfer of surface molecules from
antigen-presenting cells to lymphocytes as an active
mechanism [62]. Likewise, trogocytosis has been ob-
served between MSC and cancer cells. Thus, ovarian
cancer cells captured stromal membrane patches result-
ing in chemoresistance [63]. Moreover, trogocytosis has
been suggested during interaction of MSC with a variety
of tumor cells including ovarian cancer and breast
cancer cells [38].
Cell fusion
The closest/strongest and most complex interaction be-
tween MSC and cancer cells is the formation of fusion
or hybrid cells which also represents a very rare event
whereby underlying molecular mechanisms are still not
fully understood. Co-culture of MSC with cancer cells
like breast or ovarian cancer at certain conditions in
vitro can lead to the development of hybrid cells by fu-
sion of the two parental cell lines [38]. Potential fusion
events depend on the cell density, the cell ratio of the
parental populations, the medium components and
culture conditions (ionic strength, pH, hypoxia) among
others. However, the associated signaling pathways and
the precise requirements either favoring or inhibiting
such hybrid cell formations remain unclear. Intercellu-
lar fusion in general represents an intricate and highly
regulated event which plays an important role in fun-
damental processes during development, for instance
during fertilization between sperm and egg [64]. Al-
though various studies suggest a contribution of tumor
cell hybrids to cancer metastasis, there is still little
known about cell fusion in pathophysiological pro-
cesses like cancer and the role of cell-fusion tumor
products.
Nevertheless, hybrid cells from human breast cancer
and breast epithelial cells are well characterized [65] and
spontaneously fused hybrid cells have been reported in
several co-cultures between MSC and various cancer cell
lines including breast, ovarian, lung and gastric cancer
[36, 38, 66–68]. Figure 3a exemplarily outlines a co-
culture of primary human umbilical cord-derived MSC
and the breast cancer cell line MDA-MB-231. In order
to distinguish both populations, MSC and tumor cells
were stably transduced with a lentiviral vector carrying ei-
ther the eGFP or the mCherry gene, respectively, resulting
in green-fluorescing MSCGFP and red-fluorescing MDA-
MB-231cherry. In such a co-culture system with MSC and
cancer cells, yellow-fluorescing hybrid cells are spontan-
eously formed within 3 to 6 days whereby the cell size and
shape varies depending on the culture conditions and the
contribution of parental cell populations [36].
Besides the labeling of both parental cell lines with
fluorescent lentiviral vectors, another system has been
applied to clearly identify hybrid cells in a co-culture.
The so-called bimolecular fluorescence complementa-
tion involves a lentiviral transduction of both parental
cells as well whereby the eGFP gene is separated into
two non-fluorescent halves and each cell type is trans-
fected with one of these halves. Consequently, only a
fusion between a mesenchymal stem cell and a cancer
cell can bring these two different halves together result-
ing in a functional GFP fluorescence after expression
that is detectable via fluorescence microscopy or flow
cytometry [66].
Fused hybrid cells generated in a labeled co-culture
can be isolated by FACS and subsequent single cell
cloning [68]. A successful isolation and expansion of one
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single cell clone derived from a co-culture between
MSCGFP and MDA-MB-231cherry is displayed in Fig. 3b.
Whereas knowledge about tumor cell fusion remains
scarce, certain characteristics of properties and functions
are available about MSC-cancer hybrid cells.
Formation of hybrid populations was reported in vari-
ous studies between MSC and breast cancer as well as
ovarian cancer cells [14, 36, 38]. Moreover, in vitro fu-
sion was documented in MSC which were derived from
human embryonic stem cells and fused with various
breast cancer cell lines including MDA-MB-231, T47D,
MCF7 and MCF10A. These hybrids acquired character-
istics from both parental cell types (MSC and breast
cancer cell) such as enhanced migratory capacity and
expressed high motility like MSC, but their migration
movement was nondirectional similar to the breast
cancer cells [66]. Likewise, a higher migration rate and
concomitant acquisition of distinct MSC-like character-
istics was assigned to breast cancer hybrids [69]. The ac-
quisition of some stemness properties was suggested in
hybrid cells generated from MSC with gastric cancer
cells including increased expression of Oct4, Nanog,
Sox2 and Lin28. Moreover, expression of CD44 and
CD133 on hybrid cells was elevated compared to paren-
tal gastric cancer cells. In addition, gastric cancer fusion
cells featured a higher proliferative capacity as compared
to the parental cell lines [68].
A variety of important questions concerning tumor hy-
brid cells remain to be elucidated with respect to the ex-
istence, frequency and mechanisms of formation in vivo
as well as to the role of these fused cell types in tumori-
genesis and initiation of metastasis. At least breast and
gastric cancer hybrids provide evidence for enhanced
tumorigenic and metastatic properties [68, 69]. Nonethe-
less, several further questions include cell biological
properties, chemosensitivities and -resistance and a pos-
sible relationship to cancer stem cells [70].
Molecular and functional consequences during
interaction of MSC with tumor cells
During the multistep procedure of tumorigenesis, inter-
cellular communication of diverse cell types within the
Fig. 3 Formation and culture of tumor hybrid cells after spontaneous cell fusion. a Co-culture of MSCGFP with MDA-MB-231cherry breast cancer
cells demonstrating the development of fusion cells which are indicated by white arrows. Scale bars represent 200 μM. b Mono-culture of isolated
and expanded MDA-hybrid2 cells exhibiting dual fluorescence from both maternal cell populations (MSCGFP and MDA-MB-231cherry). Scale bars
represent 100 μM
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TME contributes to the malignancy of primary tumor
cells as well as their metastatic ability [71]. In co-culture
models of MSC populations together with different
kinds of breast and ovarian tumor cells, MSC increase
the proliferation of cancer cells [38]. Multiple cellular
interactions between MSC and breast cancer cells are
accompanied by increased growth of breast cancer both
in vitro and in vivo [72] including MSC-mediated induc-
tion of CD90 expression in the tumor cells. This transi-
ent CD90 expression in breast cancer cells results from
different kinds of interactions during co-culture with
MSC such as microparticles, notch signaling, GJIC or
nanotube formation [36–38]. Of interest, MSC function-
ality can alter during chemotherapy displaying different
effects on breast cancer cells [73]. Whereas MSC exhibit
close vicinity to breast cancer cells within the tumor
microenvironment, there are also cellular interactions
observed between MSC and normal human mammary
epithelial cells (HMEC) which are usually localized in
the normal fibroglandular breast tissue [38].
In ovarian cancer cells, MSC can induce further
surface markers besides expression of CD90 such as
functional CD73 and CD105. Thus, primary small cell
hypercalcemic ovarian carcinoma cells (SCCOHT-1) ac-
quired the capability to metabolize cyclic adenosine 3’,
5’-monophosphate (cAMP) underlining the bidirectional
molecular exchange between tumor cells and MSC [38].
Moreover, up-regulated mitotic spindle-associated
factors (MZT2A) and epithelial mitogens (EPGN) sug-
gested the promotion of proliferative capacity in ovarian
cancer cells. In parallel, a down-modulation of transcrip-
tion factors like TAL1, transcripts of the basic helix-
loop-helix family FOS and FOSB, HES1 and HES5 are
also related to the promotion of cancer development. In
addition, growth factors of the bone morphogenetic pro-
tein family were acquired by ovarian cancer cells in the
presence of MSC [38], whereby overactivation of BMP
signaling contributes to the development of certain
adenocarcinoma. Together, gene inductions during MSC
and cancer cell co-culture demonstrated that MSC not
only support ovarian cancer cell proliferation capacity
but also induce pro-metastatic properties of ovarian can-
cer cells [74]. Vice versa by looking at MSC, mutual
functional alteration during co-culture with tumor cells
also include a variety of different gene transcripts which
are up- or down-regulated in these stroma/stem cells as
analyzed by RNA microarrays [38, 74]. Of interest, MSC
expressed increasing levels of epithelial cell-specific tran-
scripts including a group of KRT family genes, which are
involved in the production of keratins for supporting the
structural framework requirements of epithelial cells.
Also certain cell-to-cell interaction related genes, inter-
cellular junction DSP gene, the cell-cell adhesion-related
genes MPZL2 and SCEL, and the calcium-dependent
cell-cell adhesion glycoprotein gene CDH1 are all up-
regulated in MSC after co-culture with ovarian cancer
cells. Conversely, a variety of cytokine mRNAs such as
CSF3, IL1A, CCL20, LIF, TNF, CXCL1, CXCL2, CXCL3,
and CXCL12 are down-regulated in MSC in the pres-
ence of ovarian cancer cells [38].
Furthermore, undetectable expression of the epithelial
cell adhesion molecule (EpCAM) in normal MSC signifi-
cantly increased both, at the mRNA and protein level
after co-culture with different ovarian cancer cell lines
such as SK-OV-3 or NIH:OVCAR-3 [38]. Together these
findings substantiate that MSC gain certain epithelial-
like cell functionalities during interaction with ovarian
cancer cells and may therefore develop an aberrant and
more tumor-associated phenotype. Therefore, the mu-
tual bidirectional interactions further suggest a more
epithelial-type conversion of MSC compared to transi-
tional properties of mesenchymal characteristics in the
ovarian cancer cells.
MSC and cancer stem cells
Previous work presented evidence for tumor-initiating
cells (TIC) in mammary carcinoma also termed cancer
stem cells (CSC) with increased expression of mesenchy-
mal characteristics including vimentin, fibronectin and
N-cadherin instead of E-cadherin [75]. Moreover, low
expression of GPI-anchored sialoglycoprotein cell adhe-
sion molecule CD24 paralleled by high expression of the
hyaluronan receptor CD44 as well as expression of alde-
hyde dehydrogenase 1 are attributed with CSC. Further
studies in mammary tumors revealed that IL6 produced
by cancer cells interacts with IL6 receptor on aldehyde
dehydrogenase 1-positive mesenchymal cells, whereby
this IL6 signaling-mediated chemotaxis may facilitate re-
cruitment of further MSC to the tumor microenviron-
ment and induction of CXCL7 production by these cells.
Vice versa, MSC-derived CXCL7 stimulates the cancer
cells via activation of the CXCR2 receptor and induces
the synthesis of additional cytokines such as IL6 and IL8
to generate a positive feedback loop which contributes
to increased MSC attraction and enhanced interactions
with tumor cells [76].
Following continuous mutual interaction within the
TME, cytokines and particularly IL1 released by tumor
cells can stimulate arachidonic acid metabolism and sub-
sequent PGE2 production in MSC. Vice versa, released cy-
tokines and PGE2 together can induce β-catenin signaling
in the neoplastic cells which contributes to the develop-
ment of more immature stem cell-like properties [41].
During these interactions characteristics of a mesen-
chymal phenotype are progressively acquired by the can-
cer cells [36–38] which may include a MSC-mediated
epithelial-to-mesenchymal transition (EMT) in the can-
cer cells. This suggests a retrodifferentiation process of
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cancer cells into a stem cell–like phenotype [77, 78]
which involves a potential carcinoma stem cell niche
(CSCN) [41] provided by interaction of MSC with can-
cer cells. A corresponding niche-forming property has
been assigned to MSC by displaying the capacity to
organize the hematopoietic stem cell niche [79, 80]. Al-
ternatively, during cellular interactions or reprogram-
ming MSC can acquire functional properties from the
cancer cells which are displayed in an altered tumor-
associated mesenchymal stem cell phenotype. Such onco-
genic reprogramming can transform MSC into aggressive
sarcoma cells [81] and may also play a role in tumors with
mesenchymal characteristics such as desmoid tumor [82].
Consequently, the newly arising cancer cell populations
after EMTand interaction display an enhanced phenotypic
plasticity including metastatic potential and altered re-
sponsiveness/resistance to therapeutic approaches.
MSC interactions and epithelial-mesenchymal transition
(EMT)
Conversion of epithelial cells into a mesenchymal pheno-
type termed as EMT is a prerequisite in physiological
processes during early stages of embryonic development
including gastrulation and myogenesis [83]. However,
EMT is also involved in pathological events such as fibro-
sis, tumor development and metastasis whereby TGF-β
signaling plays an important role [84–86]. EMT as a bio-
logical process allows an epithelial cell to undergo com-
plex multiple changes of its cell pattern and morphology
which leads to a mesenchymal cell phenotype. This transi-
tion is generally delineated by changes of epithelial-like
cell properties, for instance 1) down-modulation of
E-cadherin for loss apico-basal polarity and cell-cell
adhesion, 2) secretion of enzymes such as matrix metallo-
proteinases to degrade the ECM, and 3) upregulation of
mesenchymal markers, e.g. vimentin, N-cadherin and fi-
bronectin, all of which are paralleled by elevated migra-
tion, acquired invasiveness and increased resistance to
apoptosis [83, 85, 87].
EMT has been implicated in several tumors including
breast, ovarian and colon cancer [88–91]. In previous
studies, a plethora of oncogenic EMT inducers have
been characterized which comprise the EMT transcrip-
tions factors (EMT-TF) Snail1/2, Slug, Twist1 and Zeb1/2
and signaling pathways such as TGFβ and Wnt [92].
Besides the overall common function of the EMT-TF in
repressing E-cadherin for loss of cell adhesion, Snail and
Slug also regulate tight junction stability and protease
expression while Twist1 induces mesenchymal gene ex-
pression [83, 93].
Recently, it has been demonstrated that colon cancer
cells increased expression of EMT-TF such as Zeb1/2,
Slug, Snail and Twist which was paralleled by a down-
regulation of E-cadherin expression. Moreover, these
colon cancer cells acquired the expression of stemness
genes including Oct4 and Sox2 after co-culture with adi-
pose tissue-derived MSC. Additionally, the morphology
of colon cancer cells was altered to an elongated,
fibroblast-like cell shape underlying the conversion to a
mesenchymal phenotype. Vice versa, colon cancer cells
were able to induce secretion of cytokines (TNFα, IL10,
IFNγ) and metastasis-related factors (VEGFC, MMPs) in
MSC via activation of Wnt signaling which in turn re-
sulted in activation of Wnt pathways in colon cancer
cells. Of interest, inhibition of Wnt signaling reduced
the invasiveness and tumorigenicity of cancer cells both
in vitro and in vivo [94].
Besides these direct interactions between MSC and
colon cancer cells leading to induction of EMT and
higher invasiveness, indirect interactions also resulted in
EMT induction. Adipose tissue-derived MSC can alter
cell confluence and migration of SKBR3 breast cancer
cells, increase mammosphere formation, induce EMT, and
alter tumor cell morphology [95]. These features were at-
tributed to molecular changes induced by MSC-secreted
cytokines and chemokines in breast cancer cells.
Nasopharyngeal carcinoma (NPC) cells exhibited a
higher proliferation and migration capacity after uptake
of MSC-derived exosomes. Moreover, EMT markers
were significantly altered after uptake of exosomes includ-
ing down-modulation of E-cadherin and upregulation of
vimentin and N-cadherin. This indirect communication
between MSC-derived exosomes and cancer cells induced
EMT, promoted tumor growth in vitro and in vivo and
metastasis [96].
Further studies substantiate the occurrence of direct
and indirect MSC-cancer cell interactions leading to in-
duction of EMT, thereby altering the cell pattern and
morphology of cancer cells to a mesenchymal pheno-
type which facilitates metastasis to distant tumor sites
[38, 41, 97–99].
Conclusions
Different types of intercellular communication both,
indirect and/or direct between MSC and tumor cells
(from solid cancers of the breast, ovar, colon, etc.) in-
volve mutual functional alterations whereby the tumor
cells acquire certain mesenchymal properties. Depending
on the type and the extent of cellular interaction, even
completely new tumor cell populations can be formed in
the rare event of a MSC and tumor cell fusion. In
addition, MSC which are recruited to the invasive tumor
sites to initiate regenerative potential are progressively
altered into an aberrant MSC phenotype to function-
ally support tumor cell survival. Therefore, tumor-
associated aberrant MSC are involved in tumor cell
protection and consequently, contribute to certain ef-
fects of chemotherapeutic resistance either directly by
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expression of protective extracellular matrix pro-
teins as a drug barrier and/or indirectly by promoting
EMT of tumor cells and participating in a carcinoma
stem cell niche. Such development includes the interplay
with various other tumor-associated cell populations and
restructure of the ECM, furthermore highlighting the
tumor microenvironment as potential therapeutic anti-
tumor target.
Acknowledgements
The authors declare no financial, personal, or professional conflict of interest.
All authors have critically read and approved this work. YY is supported by a
postdoctoral fellowship from the DAAD and CSC. This work was supported
by a grant from the Erich und Gertrud Roggenbuck-Stiftung for Cancer
Research to RH.
Funding
YY is supported by a postdoctoral fellowship from the DAAD and CSC. This
work was supported by a grant from the Erich und Gertrud Roggenbuck-
Stiftung for Cancer Research to RH.
Availability of data and materials
Not applicable.
Authors’ contributions
CM, YY and RH drafted the manuscript. Figures were designed by CM and
YY and finalized by RH. The manuscript was structured by RH. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All authors have critically read and approved this work.
Ethical approval and consent to participate
Not applicable.
Author details
1Biochemistry and Tumor Biology Lab, Department of Obstetrics and
Gynecology, Hannover Medical School, Carl-Neuberg-Str. 1, D, 30625
Hannover, Germany. 2Tongji Hospital Affiliated Tongji University, Shanghai,
China.
Received: 28 July 2016 Accepted: 2 September 2016
References
1. Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of
the microenvironment in restraining cancer progression. Nat Med.
2011;17(3):320–9.
2. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer.
2001;1(1):46–54.
3. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a
glance. J Cell Sci. 2012;125(Pt 23):5591–6.
4. Whiteside TL. The tumor microenvironment and its role in promoting
tumor growth. Oncogene. 2008;27(45):5904–12.
5. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune
contexture in human tumours: impact on clinical outcome. Nat Rev
Cancer. 2012;12(4):298–306.
6. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP.
Evidence for an antigen-driven humoral immune response in medullary
ductal breast cancer. Cancer Res. 2001;61(21):7889–99.
7. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit
induction of T cell-dependent tumor immunity. Nat Med. 1998;4(5):627–30.
8. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K,
Hokita S, Aikou T. Prognostic value of intratumoral natural killer cells in
gastric carcinoma. Cancer. 2000;88(3):577–83.
9. Zamarron BF, Chen W. Dual roles of immune cells and their factors in
cancer development and progression. Int J Biol Sci. 2011;7(5):651–8.
10. Hanahan D, Coussens LM. Accessories to the crime: functions of cells
recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–22.
11. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological,
and pathological perspectives, problems, and promises. Dev Cell.
2011;21(2):193–215.
12. Cooke VG, LeBleu VS, Keskin D, Khan Z, O’Connell JT, Teng Y, Duncan MB,
Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR,
Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-
mesenchymal transition and metastasis mediated by met signaling
pathway. Cancer Cell. 2012;21(1):66–81.
13. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini 3rd F. Concise review:
dissecting a discrepancy in the literature: do mesenchymal stem cells
support or suppress tumor growth? Stem Cells. 2011;29(1):11–9.
14. Hass R, Otte A. Mesenchymal stem cells as all-round supporters in a normal
and neoplastic microenvironment. Cell Commun Signal. 2012;10(1):26.
15. Rhee KJ, Lee JI, Eom YW. Mesenchymal stem cell-mediated effects of tumor
support or suppression. Int J Mol Sci. 2015;16(12):30015–33.
16. Barcellos-de-Souza, P., G. Comito, C. Pons-Segura, M.L. Taddei, V. Gori, V.
Becherucci, F. Bambi, F. Margheri, A. Laurenzana, M. Del Rosso, P. Chiarugi.
Mesenchymal Stem Cells are Recruited and Activated into Carcinoma-
Associated Fibroblasts by Prostate Cancer Microenvironment-Derived TGF-
beta1. Stem Cells, 2016. doi: 10.1002/stem.2412.
17. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix:
drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430–9.
18. Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett.
2015;368(1):7–13.
19. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White
JG, Keely PJ. Collagen density promotes mammary tumor initiation and
progression. BMC Med. 2008;6:11.
20. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K,
Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM. Matrix
crosslinking forces tumor progression by enhancing integrin signaling. Cell.
2009;139(5):891–906.
21. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of
human mesenchymal stem cells (MSC): a comparison of adult and neonatal
tissue-derived MSC. Cell Commun Signal. 2011;9:12.
22. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol.
2009;217(2):318–24.
23. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage
potential of adult human mesenchymal stem cells. Science. 1999;
284(5411):143–7.
24. Bianco P. “Mesenchymal” stem cells. Annu Rev Cell Dev Biol. 2014;30:677–704.
25. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining
multipotent mesenchymal stromal cells. The international society for cellular
therapy position statement. Cytotherapy. 2006;8(4):315–7.
26. Hoffmann, A., T. Floerkemeier, C. Melzer, R. Hass. Comparison of in vitro-
cultivation of human mesenchymal stroma/stem cells derived from bone
marrow and umbilical cord. J Tissue Eng Regen Med. 2016. doi:10.1002/
term.2153.
27. Otte A, Bucan V, Reimers K, Hass R. Mesenchymal stem cells maintain long-
term in vitro stemness during explant culture. Tissue Eng Part C Methods.
2013;19(12):937–48.
28. Yang Y, Melzer C, Bucan V, von der Ohe J, Otte A, Hass R. Conditioned
umbilical cord tissue provides a natural three-dimensional storage
compartment as in vitro stem cell niche for human mesenchymal stroma/
stem cells. Stem Cell Res Ther. 2016;7:28.
29. Majore I, Moretti P, Hass R, Kasper C. Identification of subpopulations in
mesenchymal stem cell-like cultures from human umbilical cord. Cell
Commun Signal. 2009;7:6.
30. Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in
human bone marrow by a novel monoclonal antibody, STRO-1. Blood.
1991;78(1):55–62.
31. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B,
Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM,
Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Peault B. A
perivascular origin for mesenchymal stem cells in multiple human organs.
Cell Stem Cell. 2008;3(3):301–13.
Melzer et al. Cell Communication and Signaling  (2016) 14:20 Page 10 of 12
32. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE.
Human bone marrow stromal cells express a distinct set of biologically
functional chemokine receptors. Stem Cells. 2006;24(4):1030–41.
33. Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huenecke S, Amara C, Koller
S, Rettinger E, Grez M, Koehl U, Latifi-Pupovci H, Henschler R, Tonn T, von
Laer D, Klingebiel T, Bader P. CD271 antigen defines a subset of multipotent
stromal cells with immunosuppressive and lymphohematopoietic
engraftment-promoting properties. Haematologica. 2010;95(4):651–9.
34. Kuroda Y, Kitada M, Wakao S, Nishikawa K, Tanimura Y, Makinoshima H,
Goda M, Akashi H, Inutsuka A, Niwa A, Shigemoto T, Nabeshima Y,
Nakahata T, Nabeshima Y, Fujiyoshi Y, Dezawa M. Unique multipotent
cells in adult human mesenchymal cell populations. Proc Natl Acad Sci
U S A. 2010;107(19):8639–43.
35. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL,
Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour
stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.
36. Mandel K, Yang Y, Schambach A, Glage S, Otte A, Hass R. Mesenchymal
stem cells directly interact with breast cancer cells and promote tumor cell
growth in vitro and in vivo. Stem Cells Dev. 2013;22(23):3114–27.
37. Yang Y, Bucan V, Baehre H, von der Ohe J, Otte A, Hass R. Acquisition
of new tumor cell properties by MSC-derived exosomes. Int J Oncol.
2015;47(1):244–52.
38. Yang Y, Otte A, Hass R. Human mesenchymal stroma/stem cells exchange
membrane proteins and alter functionality during interaction with different
tumor cell lines. Stem Cells Dev. 2015;24(10):1205–22.
39. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11–5.
40. Chiarugi P, P. Cirri. Metabolic exchanges within tumor microenvironment.
Cancer Lett. 2016;380:272–80.
41. Li HJ, Reinhardt F, Herschman HR, Weinberg RA. Cancer-stimulated
mesenchymal stem cells create a carcinoma stem cell niche via
prostaglandin E2 signaling. Cancer Discov. 2012;2(9):840–55.
42. Yuan Y, Lu X, Tao CL, Chen X, Shao HW, Huang SL. Forced expression of
indoleamine-2,3-dioxygenase in human umbilical cord-derived
mesenchymal stem cells abolishes their anti-apoptotic effect on leukemia
cell lines in vitro. In Vitro Cell Dev Biol Anim. 2013;49(10):752–8.
43. Naderi EH, Findley HW, Ruud E, Blomhoff HK, Naderi S. Activation of cAMP
signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through
abrogation of p53 accumulation. Blood. 2009;114(3):608–18.
44. Naderi EH, Jochemsen AG, Blomhoff HK, Naderi S. Activation of cAMP signaling
interferes with stress-induced p53 accumulation in ALL-derived cells by
promoting the interaction between p53 and HDM2. Neoplasia. 2011;13(7):653–63.
45. Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML,
Josefsen D, Ruud E, Naderi S, Blomhoff HK. Bone marrow stroma-derived
PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation
and cell death. Mol Cancer. 2015;14:14.
46. Otte A, Rauprich F, von der Ohe J, Hillemanns P, Hass R. Interference of
Ca(2)(+) with the proliferation of SCCOHT-1 and ovarian adenocarcinoma
cells. Int J Oncol. 2014;45(3):1151–8.
47. Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici M,
Kusuzaki K, Baldini N. Role of mesenchymal stem cells in osteosarcoma and
metabolic reprogramming of tumor cells. Oncotarget. 2014;5(17):7575–88.
48. Peppicelli S, Bianchini F, Calorini L. Extracellular acidity, a “reappreciated”
trait of tumor environment driving malignancy: perspectives in diagnosis
and therapy. Cancer Metastasis Rev. 2014;33(2-3):823–32.
49. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular
vesicles for genetic information transfer and gene therapy. Hum Mol Genet.
2012;21(R1):R125–34.
50. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity
and reciprocity. Cell. 2011;147(5):992–1009.
51. Vallabhaneni KC, Penfornis P, Dhule S, Guillonneau F, Adams KV, Mo YY, Xu
R, Liu Y, Watabe K, Vemuri MC, Pochampally R. Extracellular vesicles from
bone marrow mesenchymal stem/stromal cells transport tumor regulatory
microRNA, proteins, and metabolites. Oncotarget. 2015;6(7):4953–67.
52. Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z, Clayton A. Cancer
exosomes trigger mesenchymal stem cell differentiation into pro-
angiogenic and pro-invasive myofibroblasts. Oncotarget. 2015;6(2):715–31.
53. Wu S, Ju GQ, Du T, Zhu YJ, Liu GH. Microvesicles derived from human
umbilical cord Wharton’s jelly mesenchymal stem cells attenuate bladder
tumor cell growth in vitro and in vivo. PLoS One. 2013;8(4):e61366.
54. Del Papa B, Sportoletti P, Cecchini D, Rosati E, Balucani C, Baldoni S,
Fettucciari K, Marconi P, Martelli MF, Falzetti F, Di Ianni M. Notch1
modulates mesenchymal stem cells mediated regulatory T-cell induction.
Eur J Immunol. 2013;43(1):182–7.
55. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the
activation mechanism. Cell. 2009;137(2):216–33.
56. Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase
inhibitor blocks Notch signaling in vivo and causes a severe neurogenic
phenotype in zebrafish. EMBO Rep. 2002;3(7):688–94.
57. Kabashima-Niibe A, Higuchi H, Takaishi H, Masugi Y, Matsuzaki Y, Mabuchi Y,
Funakoshi S, Adachi M, Hamamoto Y, Kawachi S, Aiura K, Kitagawa Y,
Sakamoto M, Hibi T. Mesenchymal stem cells regulate epithelial-
mesenchymal transition and tumor progression of pancreatic cancer cells.
Cancer Sci. 2013;104(2):157–64.
58. Kandouz M, Batist G. Gap junctions and connexins as therapeutic targets in
cancer. Expert Opin Ther Targets. 2010;14(7):681–92.
59. Gurke S, Barroso JF, Gerdes HH. The art of cellular communication: tunneling
nanotubes bridge the divide. Histochem Cell Biol. 2008;129(5):539–50.
60. Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, Polycarpe D,
Sadelain M, Larson SM. Intercellular transfer of P-glycoprotein mediates
acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A.
2005;102(6):1933–8.
61. Caicedo A, Fritz V, Brondello JM, Ayala M, Dennemont I, Abdellaoui N, de
Fraipont F, Moisan A, Prouteau CA, Boukhaddaoui H, Jorgensen C, Vignais
ML. MitoCeption as a new tool to assess the effects of mesenchymal stem/
stromal cell mitochondria on cancer cell metabolism and function. Sci Rep.
2015;5:9073.
62. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat
Immunol. 2003;4(9):815.
63. Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E, Mery E,
Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, Dagonnet F, Fournie JJ,
Marie JP, Pujade-Lauraine E, Favre G, Soria J, Mirshahi M. Oncologic
trogocytosis of an original stromal cells induces chemoresistance of ovarian
tumours. PLoS One. 2008;3(12):e3894.
64. Ogle BM, Cascalho M, Platt JL. Biological implications of cell fusion. Nat Rev
Mol Cell Biol. 2005;6(7):567–75.
65. Tosun S, Fried S, Niggemann B, Zanker KS, Dittmar T. Hybrid Cells Derived
from Human Breast Cancer Cells and Human Breast Epithelial Cells Exhibit
Differential TLR4 and TLR9 Signaling. Int J Mol Sci. 2016;17(5).
66. Noubissi FK, Harkness T, Alexander CM, Ogle BM. Apoptosis-induced
cancer cell fusion: a mechanism of breast cancer metastasis. FASEB J.
2015;29(9):4036–45.
67. Wei HJ, Nickoloff JA, Chen WH, Liu HY, Lo WC, Chang YT, Yang PC, Wu CW,
Williams DF, Gelovani JG, Deng WP. FOXF1 mediates mesenchymal stem
cell fusion-induced reprogramming of lung cancer cells. Oncotarget.
2014;5(19):9514–29.
68. Xue J, Zhu Y, Sun Z, Ji R, Zhang X, Xu W, Yuan X, Zhang B, Yan Y, Yin L, Xu
H, Zhang L, Zhu W, Qian H. Tumorigenic hybrids between mesenchymal
stem cells and gastric cancer cells enhanced cancer proliferation, migration
and stemness. BMC Cancer. 2015;15:793.
69. Rappa G, Mercapide J, Lorico A. Spontaneous formation of tumorigenic
hybrids between breast cancer and multipotent stromal cells is a source of
tumor heterogeneity. Am J Pathol. 2012;180(6):2504–15.
70. Dittmar T, Nagler C, Niggemann B, Zanker KS. The dark side of stem cells:
triggering cancer progression by cell fusion. Curr Mol Med. 2013;13(5):735–50.
71. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R. Interaction of tumor
cells with the microenvironment. Cell Commun Signal. 2011;9:18.
72. Muehlberg FL, Song YH, Krohn A, Pinilla SP, Droll LH, Leng X, Seidensticker
M, Ricke J, Altman AM, Devarajan E, Liu W, Arlinghaus RB, Alt EU. Tissue-
resident stem cells promote breast cancer growth and metastasis.
Carcinogenesis. 2009;30(4):589–97.
73. Skolekova S, Matuskova M, Bohac M, Toro L, Durinikova E, Tyciakova S,
Demkova L, Gursky J, Kucerova L. Cisplatin-induced mesenchymal stromal
cells-mediated mechanism contributing to decreased antitumor effect in
breast cancer cells. Cell Commun Signal. 2016;14:4.
74. Lis R, Touboul C, Halabi NM, Madduri AS, Querleu D, Mezey J, Malek JA,
Suhre K, Rafii A. Mesenchymal cell interaction with ovarian cancer cells
induces a background dependent pro-metastatic transcriptomic profile.
J Transl Med. 2014;12:59.
75. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J,
Weinberg RA. The epithelial-mesenchymal transition generates cells with
properties of stem cells. Cell. 2008;133(4):704–15.
Melzer et al. Cell Communication and Signaling  (2016) 14:20 Page 11 of 12
76. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath
A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS. Breast
cancer stem cells are regulated by mesenchymal stem cells through
cytokine networks. Cancer Res. 2011;71(2):614–24.
77. Hass R. Retrodifferentiation–a mechanism for cellular regeneration? Biol
Chem. 2009;390(5-6):409–16.
78. Hass R, Gunji H, Datta R, Kharbanda S, Hartmann A, Weichselbaum R, Kufe
D. Differentiation and retrodifferentiation of human myeloid leukemia cells
is associated with reversible induction of cell cycle-regulatory genes. Cancer
Res. 1992;52(6):1445–50.
79. Bianco P. Bone and the hematopoietic niche: a tale of two stem cells.
Blood. 2011;117(20):5281–8.
80. Friedenstein AJ, Latzinik NW, Grosheva AG, Gorskaya UF. Marrow
microenvironment transfer by heterotopic transplantation of freshly isolated
and cultured cells in porous sponges. Exp Hematol. 1982;10(2):217–27.
81. Eid JE, Garcia CB. Reprogramming of mesenchymal stem cells by
oncogenes. Semin Cancer Biol. 2015;32:18–31.
82. Wu C, Amini-Nik S, Nadesan P, Stanford WL, Alman BA. Aggressive
fibromatosis (desmoid tumor) is derived from mesenchymal progenitor
cells. Cancer Res. 2010;70(19):7690–8.
83. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in
cancer: parallels between normal development and tumor progression.
J Mammary Gland Biol Neoplasia. 2010;15(2):117–34.
84. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV,
Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and
not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol.
2010;176(1):85–97.
85. Smith B.N, N.A. Bhowmick. Role of EMT in Metastasis and Therapy
Resistance. J Clin Med, 2016. 5(2).
86. Laurenzana A, Biagioni A, Bianchini F, Peppicelli S, Chilla A, Margheri F,
Luciani C, Pimpinelli N, Del Rosso M, Calorini L, Fibbi G. Inhibition of uPAR-
TGFbeta crosstalk blocks MSC-dependent EMT in melanoma cells. J Mol
Med (Berl). 2015;93(7):783–94.
87. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition.
J Clin Invest. 2009;119(6):1420–8.
88. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A,
Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-
mesenchymal transition, mesenchymal-epithelial transition, stem cells and
beta-catenin. Cells Tissues Organs. 2005;179(1-2):56–65.
89. Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM, Creasap N,
Rosol TJ, Robinson ML, Eng C, Ostrowski MC, Leone G. Direct evidence
for epithelial-mesenchymal transitions in breast cancer. Cancer Res.
2008;68(3):937–45.
90. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, Salzet M.
Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett.
2010;291(1):59–66.
91. Chaturvedi S, Hass R. Extracellular signals in young and aging breast
epithelial cells and possible connections to age-associated breast cancer
development. Mech Ageing Dev. 2011;132(5):213–9.
92. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-
mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96.
93. Lv N, Shan Z, Gao Y, Guan H, Fan C, Wang H, Teng W. Twist1 regulates the
epithelial-mesenchymal transition via the NF-kappaB pathway in papillary
thyroid carcinoma. Endocrine. 2016;51(3):469–77.
94. Chen D, Liu S, Ma H, Liang X, Ma H, Yan X, Yang B, Wei J, Liu X. Paracrine
factors from adipose-mesenchymal stem cells enhance metastatic capacity
through Wnt signaling pathway in a colon cancer cell co-culture model.
Cancer Cell Int. 2015;15:42.
95. Kucerova L, Skolekova S, Matuskova M, Bohac M, Kozovska Z. Altered
features and increased chemosensitivity of human breast cancer cells
mediated by adipose tissue-derived mesenchymal stromal cells. BMC
Cancer. 2013;13:535.
96. Shi S, Zhang Q, Xia Y, You B, Shan Y, Bao L, Li L, You Y, Gu Z. Mesenchymal
stem cell-derived exosomes facilitate nasopharyngeal carcinoma
progression. Am J Cancer Res. 2016;6(2):459–72.
97. Li T, Zhang C, Ding Y, Zhai W, Liu K, Bu F, Tu T, Sun L, Zhu W, Zhou F, Qi W,
Hu J, Chen H, Sun X. Umbilical cord-derived mesenchymal stem cells
promote proliferation and migration in MCF-7 and MDA-MB-231
breast cancer cells through activation of the ERK pathway. Oncol Rep.
2015;34(3):1469–77.
98. Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, Miller N,
Hennessy E, Dockery P, Barry FP, O’Brien T, Kerin MJ. Potential role of
mesenchymal stem cells (MSCs) in the breast tumour microenvironment:
stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res
Treat. 2010;124(2):317–26.
99. So KA, Min KJ, Hong JH, Lee JK. Interleukin-6 expression by interactions
between gynecologic cancer cells and human mesenchymal stem cells
promotes epithelial-mesenchymal transition. Int J Oncol. 2015;47(4):1451–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Melzer et al. Cell Communication and Signaling  (2016) 14:20 Page 12 of 12
